Burning Rock Biotech Limited (BNR)

The total asset value of Burning Rock Biotech Limited (BNR) stood at $ 1,243 Mln as on 30-Sep-24

The share price of Burning Rock Biotech Limited (BNR) is $2.89 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Burning Rock Biotech Limited (BNR) has given a return of -20.81% in the last 3 years.

Burning Rock Biotech Limited (BNR) has a market capitalisation of $ 30 Mln as on 28-Apr-2025. As per Value Research classification, it is a company.

The P/B ratio of Burning Rock Biotech Limited (BNR) is 0.37 times as on 28-Apr-2025, a 86% discount to its peers’ median range of 2.59 times.

Since, TTM earnings of Burning Rock Biotech Limited (BNR) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Burning Rock Biotech Limited (BNR) and enter the required number of quantities and click on buy to purchase the shares of Burning Rock Biotech Limited (BNR).

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. Address: No. 5, Xingdao Ring Road North, Guangzhou, China, 510005

The CEO & director of Mr. Yusheng Han. is Burning Rock Biotech Limited (BNR), and CFO & Sr. VP is Mr. Yusheng Han.

There is no promoter pledging in Burning Rock Biotech Limited (BNR).

Some of the close peers are:

No, TTM profit after tax of Burning Rock Biotech Limited (BNR) was $0 Mln.